首页> Journal of bone oncology> Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE.

Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE.

导出 LinkOut

翻译打印收藏纠错

第一作者： Daniele,Santini

第一单位： Department of Oncology, Campus Bio-Medico University, Rome, Italy.

作者： Daniele,Santini ^[1] ; Saverio,Cinieri ^[2] ; Donatello,Gasparro ^[3] ; Roberto,Bordonaro ^[4] ; Pamela Francesca,Guglielmini ^[5] ; Vincenzo Emanuele,Chiuri ^[6] ; Rolando M,D'Angelillo ^[7] ; Giovanni Luca,Ceresoli ^[8] ; Daniele,Fagnani ^[9] ; Mirko,Acquati ^[10] ; Manlio,Mencoboni ^[11] ; Gaetano,Lanzetta ^[12] ; Donata,Sartori ^[13] ; Paolo,Carlini ^[14] ; Fabiana,Panebianco ^[15] ; Patrizia,Beccaglia ^[15] ; Giuseppe,Procopio ^[16]

作者单位： Department of Oncology, Campus Bio-Medico University, Rome, Italy. ^[1] Medical Oncology Unit, Antonio Perrino Hospital, Brindisi, Italy. ^[2] Medical Oncology Unit, Department of General & Specialistic Medicine, University Hospital of Parma, Italy. ^[3] MD - ARNAS Garibaldi, Catania, Italy. ^[4] Medical Oncology Department, Ospedale SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy. ^[5] Medical Oncology Department, Ospedale Vito Fazzi, Lecce, Italy. ^[6] Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy. ^[7] Department of Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy. ^[8] Medical Oncology Division - ASST, Vimercate, Italy. ^[9] Unit of Medical Oncology, Azienda Ospedaliera San Gerardo, Monza, Italy. ^[10] Oncology Unit, Villa Scassi Hospital, 16149 Genova, Italy. ^[11] Department Oncology and Palliative Care, INI Grottaferrata, Rome, Italy. ^[12] Oncology Unit, AULSS 3, Mirano, Italy. ^[13] Division of Medical Oncology 1, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. ^[14] Medical Affairs Department, Oncology, Janssen-Cilag SpA, Cologno Monzese, Milan, Italy. ^[15] Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano, Italy. ^[16]

关键词 Abiraterone acetate Bone alkaline phosphatase Bone targeting therapy Bone turnover biomarkers C-terminal telopeptide mCRPC

DOI 10.1016/j.jbo.2020.100341

PMID 33425672

发布时间 2022-04-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览4

Journal of bone oncology

2021年26卷

100341页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览4

点击下载本期目录封面

Journal of bone oncology

2021年26卷

100341页

检索历史清除

Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE.

Journal of bone oncology

相似文献

同项目论文

Journal of bone oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE.

Journal of bone oncology

相似文献

同项目论文

Journal of bone oncology

相关期刊

检索历史清除